- Home
- MCRI vs NVCR Comparison
MCRI vs NVCR Comparison
Compare MCRI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | NVCR |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MCRI | NVCR |
|---|---|---|
| Price | $100.14 | $11.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $100.50 | $28.08 |
| AVG Volume (30 Days) | 83.7K | ★ 2.6M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 41.41 | 21.79 |
| EPS | ★ 5.43 | N/A |
| Revenue | $395,377,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $4.85 | $7.72 |
| Revenue Next Year | $2.21 | $6.74 |
| P/E Ratio | $18.43 | ★ N/A |
| Revenue Growth | ★ 114.40 | 8.28 |
| 52 Week Low | $69.99 | $9.82 |
| 52 Week High | $113.88 | $20.05 |
Technical Indicators
Market Signals| Indicator | MCRI | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 46.12 |
| Support Level | $94.30 | $10.86 |
| Resistance Level | $106.87 | $14.13 |
| Average True Range (ATR) | 2.95 | 0.99 |
| MACD | 0.26 | -0.10 |
| Stochastic Oscillator | 69.01 | 24.61 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.